Idenix Pharmaceuticals, Inc. (IDIX) Reports Q3 Loss of 12c
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $2.56 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
